+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Bilirubin Blood Test Market by Test Type (Direct, Indirect, Total), Method (Chromatographic, Diazo, Enzymatic), End User, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013880
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Bilirubin Blood Test Market grew from USD 1.20 billion in 2024 to USD 1.34 billion in 2025. It is expected to continue growing at a CAGR of 10.87%, reaching USD 2.23 billion by 2030.

Comprehensive Foundational Overview of Bilirubin Blood Testing Highlighting Its Clinical Significance Analytical Methodologies and Patient Care Implications

The study of bilirubin blood testing occupies a central role in modern clinical diagnostics, serving as a vital indicator of liver function and overall metabolic health. Produced during the degradation of hemoglobin, bilirubin traverses through conjugation processes in the liver before being excreted. Perturbations in its concentration can reveal a spectrum of hepatic and hematologic conditions, making it an essential assay in routine health evaluations and specialized investigations alike.

Clinicians rely on precise quantification of total, direct, and indirect bilirubin levels to differentiate between physiologic and pathologic causes of hyperbilirubinemia. This differentiation not only informs diagnostic pathways but also shapes treatment strategies, whether addressing obstructive jaundice or managing neonatal screenings for inherited disorders. Technological advancements have refined assay sensitivity, reduced turnaround times, and enabled seamless integration into laboratory information management systems, thereby enhancing the reliability of clinical decision making.

From a patient perspective, early detection of bilirubin imbalances can avert progressive liver damage and improve prognoses for conditions such as cirrhosis, viral hepatitis, and inherited disorders. As healthcare providers strive to deliver personalized care, the role of high-throughput, reproducible testing platforms becomes ever more critical. This foundational overview establishes the clinical and analytical context for subsequent discussions around market dynamics, technological evolution, and operational strategies within the bilirubin blood testing arena.

Dynamic Transformation Patterns Shaping the Bilirubin Testing Landscape and Accelerating Advancements in Diagnostic Capabilities and Technologies

The bilirubin testing landscape has undergone a dramatic metamorphosis driven by automation, digital integration, and novel analytic methodologies. Laboratories that once relied solely on colorimetric assays have embraced chromatographic and enzymatic techniques to achieve enhanced specificity. Meanwhile, spectrophotometry has evolved through high-resolution detectors and refined optical pathways, enabling reliable differentiation between unconjugated and conjugated bilirubin fractions.

Parallel developments in point of care testing have introduced portable analyzers capable of delivering rapid results in critical care settings and remote clinics. Integration with electronic health record systems ensures seamless data transfer, reducing the risk of transcription errors and expediting clinician response. Furthermore, artificial intelligence-driven quality control algorithms now flag assay deviations in real time, optimizing workflow efficiency and ensuring adherence to stringent regulatory standards.

As direct, indirect, and total bilirubin measurements become more accessible across both high-volume central laboratories and decentralized testing sites, laboratories are shifting from batch-based processing toward continuous, demand-driven operations. This transformative shift not only enhances patient outcomes by accelerating diagnostic pathways but also reduces operational bottlenecks, laying the groundwork for future innovations that will further refine assay precision and broaden clinical applicability.

Comprehensive Assessment of United States Tariff Impacts on Bilirubin Blood Test Supply Chains Regulatory Compliance and Cost Structures for 2025

The imposition of new tariff measures in 2025 has introduced a complex set of challenges for manufacturers, distributors, and end users within the bilirubin testing ecosystem. Import duties on reagents, assay kits, and analytical instrumentation have increased the landed cost of critical supplies, necessitating strategic reevaluation of sourcing strategies. Suppliers are negotiating long-term procurement contracts while exploring alternative manufacturing hubs to mitigate exposure to fluctuating trade policies.

This regulatory backdrop has also prompted a recalibration of inventory management practices across clinical laboratories and diagnostic centers. Facilities are hedging against supply interruptions by deepening collaborations with domestic reagent producers and expanding buffer inventories without compromising quality standards. At the same time, direct, indirect, and total bilirubin assays must meet rigorous compliance requirements, driving both equipment vendors and laboratory managers to invest in validation studies and method verification protocols that account for tariff-induced cost variances.

Although cost structures have tightened, the situation has fostered greater collaboration among stakeholders. Cross-border partnerships and alliance networks have emerged to optimize shared resources, while manufacturers are accelerating investments in regional manufacturing footprints. These adaptive measures are enhancing supply chain resilience and preserving the continuity of bilirubin testing services despite the evolving trade landscape.

In-Depth Analytical Perspectives on Key Segmentation Insights Driving Bilirubin Blood Test Market Diversity and Specialized Diagnostic Requirements

Deep insights into market segmentation reveal nuanced opportunities and challenges across the bilirubin testing continuum. When examination is organized by test type, the direct measurement of conjugated bilirubin provides precise information on hepatic excretion efficiency, while indirect values signal hemolytic processes. The sum of these measurements, known as total bilirubin, offers a comprehensive snapshot of bilirubin metabolism. Each of these types carries unique operational and clinical requirements that laboratories must address to ensure diagnostic accuracy.

Method-based segmentation highlights five distinct approaches, each with its own technical attributes. Chromatographic technologies deliver high-resolution separation, enabling precise quantification in complex matrices. Diazo assays, long established in clinical practice, have benefited from reagent refinements that reduce interference from plasma proteins. Enzymatic methods leverage bilirubin UDP-glucuronyltransferase activity to enhance specificity, while HPLC platforms provide unparalleled resolution for research applications. Spectrophotometry remains a mainstay in many settings, offering cost-effective, rapid results through optimized absorbance measurements.

Users of bilirubin testing span a broad spectrum. Academic and research institutes pursue assay innovation and basic science applications, whereas clinical laboratories and diagnostic centers focus on high-throughput screening and routine patient monitoring. Hospitals require robust, integrated solutions that support emergency diagnostics and inpatient management, and point of care testing facilities prioritize speed and portability to inform immediate treatment decisions.

Application-driven segmentation further refines market focus. Hepatic disorders, such as alcoholic liver disease, cirrhosis, and viral hepatitis, are studied through subcategories that include hepatitis A, hepatitis B, and hepatitis C, each presenting unique epidemiological and treatment considerations. In parallel, newborn screening programs deploy bilirubin assays to detect inherited conditions early in life, underscoring the test’s indispensability across both chronic and congenital medical contexts.

Extensive Regional Exploration of Bilirubin Testing Adoption Trends and Emerging Opportunities across Major Global Geographies and Healthcare Systems

Regional dynamics exert a profound influence on the adoption and evolution of bilirubin blood tests, with distinct patterns emerging across major geographies. In the Americas, investments in healthcare infrastructure and the prevalence of liver disease have propelled demand for advanced assays and point of care solutions. Laboratories in North America are leveraging integrated data platforms to streamline testing workflows and enhance patient throughput, leading to faster diagnoses and improved outcomes.

In Europe, Middle East & Africa, variable regulatory frameworks and diverse healthcare systems shape market trajectories. Western European nations with established reimbursement models emphasize assay standardization and cross-border collaboration on reference standards, while emerging economies in Eastern Europe, the Gulf region, and North Africa are expanding diagnostic capacities through investments in training and localized manufacturing. These efforts are widening patient access to quality testing, particularly in underserved populations.

Meanwhile, the Asia-Pacific region is characterized by rapid expansion of clinical laboratory networks and increasing prevalence of liver disorders linked to lifestyle and viral hepatitis. Health authorities in several Asia-Pacific markets are implementing universal newborn screening programs that incorporate bilirubin assays, reinforcing the importance of early detection initiatives. At the same time, innovative partnerships between global diagnostic firms and regional players are accelerating technology transfer and capacity building, thereby strengthening the overall testing ecosystem.

Strategic Overview of Key Industry Leaders Shaping the Evolution of Bilirubin Blood Test Innovations Collaborations and Competitive Dynamics

Several leading diagnostics manufacturers and service providers are at the forefront of advancing bilirubin blood testing capabilities. Through strategic collaborations, research partnerships, and acquisitions, these industry players are expanding their assay portfolios to address both routine and specialized clinical needs. Investments in proprietary reagent formulations and modular analyzer platforms enable seamless integration into laboratory ecosystems, thereby reducing total cost of ownership while maintaining analytical rigor.

Technology licensure agreements have also facilitated the diffusion of novel enzymatic and chromatographic techniques to regions with growing diagnostic demand. Manufacturers are leveraging their global footprints to provide comprehensive support, from technical training to on-site calibration services. Multi-modal platforms that combine bilirubin quantification with additional liver-function biomarkers exemplify the drive toward consolidated workflows and enriched diagnostic insights.

Emerging entrants are challenging established incumbents by introducing disruptive pricing models and subscription-based reagent supply programs. These new business approaches, coupled with digital service offerings for remote monitoring and instrument diagnostics, are reshaping competitive dynamics. Ultimately, the convergence of assay innovation, value-based contracting, and lifecycle service optimization is redefining the competitive contours of the bilirubin testing market.

Action-Oriented Recommendations for Industry Leaders to Drive Innovation Enhance Operational Excellence and Strengthen Bilirubin Testing Market Positioning

Industry leaders should prioritize investment in advanced analytical methodologies to sustain diagnostic leadership. A focused enhancement of chromatographic and enzymatic capabilities will deliver superior specificity and reduce interference-related inaccuracies. Simultaneously, organizations must strengthen supplier diversification strategies to mitigate the impact of evolving trade regulations and supply chain disruptions. Cultivating relationships with regional reagent producers will ensure continuity of consumable supplies and facilitate rapid response to local regulatory requirements.

Operational excellence can be further reinforced by adopting real-time quality control systems that leverage artificial intelligence to detect assay drift and preempt calibration failures. Integration of point of care devices with centralized laboratory information systems will create unified data streams that enhance care coordination, reduce manual transcription errors, and accelerate clinical decision making. Furthermore, aligning research and development roadmaps with emerging applications such as neonatal care, alcoholic liver disease monitoring, and viral hepatitis subtyping will capture high-value market segments and support long-term growth objectives.

Lastly, forging strategic partnerships with academic institutions and research networks will foster collaborative innovation, drive standardization of testing protocols, and expedite the validation of novel biomarkers. By implementing these actionable measures, industry participants will be well positioned to capitalize on market evolution, deliver superior patient outcomes, and strengthen their competitive positioning in the bilirubin testing domain.

Rigorous Research Methodology Framework Underpinning the Bilirubin Blood Test Analysis Data Collection Validation and Insight Generation

This analysis rests on a rigorous methodological framework that began with comprehensive secondary research. Peer-reviewed journals, regulatory filings, and clinical guidelines were examined to establish a baseline understanding of bilirubin metabolism, assay technologies, and market dynamics. Concurrently, industry reports and public financial disclosures provided insight into competitive strategies, investment trends, and regional market behavior.

Primary research comprised structured interviews with laboratory directors, head of clinical chemistry, supply chain managers, and regulatory affairs experts. These dialogues elucidated real-world challenges, best practices, and emerging priorities across both centralized and decentralized testing environments. Quantitative data points were corroborated through cross-validation with multiple sources, ensuring consistency and reliability.

Advanced analytics techniques were applied to synthesize qualitative and quantitative inputs into coherent insights. Statistical analyses identified correlation patterns between regulatory shifts and cost structures, while scenario modeling assessed the impact of tariff adjustments on reagent availability and pricing. All findings underwent peer review by a panel of subject matter experts, confirming both methodological integrity and the strategic relevance of conclusions drawn in this report.

Conclusive Reflections on the Strategic Implications of Bilirubin Testing Advances and Future Outlook in Clinical Diagnostics and Patient Care

The evolution of bilirubin blood testing reflects a convergence of technological innovation, regulatory adaptation, and clinical imperatives. From foundational colorimetric assays to state-of-the-art chromatographic and enzymatic platforms, the field has advanced to meet the growing demand for precise, timely, and actionable diagnostic information. Simultaneously, global trade policies and regional market dynamics continue to shape supply chain strategies and influence cost structures.

Segmentation insights reveal the importance of tailoring approaches based on test type, analytic method, end user requirements, and specific clinical applications such as alcoholic liver disease, cirrhosis, viral hepatitis, and newborn screening. Regional nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the need for market-specific adaptations and collaborations. Industry leaders are responding through strategic alliances, investment in digital integration, and diversification of manufacturing footprints.

Looking ahead, the integration of artificial intelligence, multiplexed assay platforms, and real-time monitoring will drive the next wave of clinical innovation. Stakeholders who implement the recommendations outlined herein-focusing on analytical excellence, supply chain resilience, and targeted research collaborations-will secure a competitive advantage and deliver meaningful improvements in patient care. This conclusive perspective serves as a roadmap for navigating the complex yet opportunity-rich landscape of bilirubin blood testing.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Direct
    • Indirect
    • Total
  • Method
    • Chromatographic
    • Diazo
    • Enzymatic
    • HPLC
    • Spectrophotometry
  • End User
    • Academic & Research Institutes
    • Clinical Laboratories
    • Diagnostic Centers
    • Hospitals
    • Point Of Care Testing
  • Application
    • Hepatic Disorders
      • Alcoholic Liver Disease
      • Cirrhosis
      • Viral Hepatitis
        • Hepatitis A
        • Hepatitis B
        • Hepatitis C
    • Newborn Screening
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Sysmex Corporation
  • bioMérieux SA
  • Ortho Clinical Diagnostics Inc
  • Mindray Medical International Limited
  • DiaSorin S.p.A

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid growth of point-of-care bilirubin analyzers in neonatal intensive care units for immediate jaundice assessment
5.2. Implementation of high-throughput automated bilirubin testing platforms in clinical labs to meet rising screening demands
5.3. Emergence of noninvasive transcutaneous bilirubinometry devices to reduce newborn blood draw procedures
5.4. Integration of digital data management systems with bilirubin test workflows for real-time patient monitoring and analytics
5.5. Increased use of liquid chromatography-mass spectrometry methods for precise quantification of bilirubin isomers in liver disease diagnosis
5.6. Collaborations between diagnostics companies and telehealth providers to enable remote bilirubin monitoring and consultation
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bilirubin Blood Test Market, by Test Type
8.1. Introduction
8.2. Direct
8.3. Indirect
8.4. Total
9. Bilirubin Blood Test Market, by Method
9.1. Introduction
9.2. Chromatographic
9.3. Diazo
9.4. Enzymatic
9.5. HPLC
9.6. Spectrophotometry
10. Bilirubin Blood Test Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Clinical Laboratories
10.4. Diagnostic Centers
10.5. Hospitals
10.6. Point Of Care Testing
11. Bilirubin Blood Test Market, by Application
11.1. Introduction
11.2. Hepatic Disorders
11.2.1. Alcoholic Liver Disease
11.2.2. Cirrhosis
11.2.3. Viral Hepatitis
11.2.3.1. Hepatitis A
11.2.3.2. Hepatitis B
11.2.3.3. Hepatitis C
11.3. Newborn Screening
12. Americas Bilirubin Blood Test Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Bilirubin Blood Test Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Bilirubin Blood Test Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche Ltd
15.3.2. Abbott Laboratories
15.3.3. Siemens Healthineers AG
15.3.4. Danaher Corporation
15.3.5. Thermo Fisher Scientific Inc
15.3.6. Sysmex Corporation
15.3.7. bioMérieux SA
15.3.8. Ortho Clinical Diagnostics Inc
15.3.9. Mindray Medical International Limited
15.3.10. DiaSorin S.p.A
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BILIRUBIN BLOOD TEST MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BILIRUBIN BLOOD TEST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BILIRUBIN BLOOD TEST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. BILIRUBIN BLOOD TEST MARKET: RESEARCHAI
FIGURE 24. BILIRUBIN BLOOD TEST MARKET: RESEARCHSTATISTICS
FIGURE 25. BILIRUBIN BLOOD TEST MARKET: RESEARCHCONTACTS
FIGURE 26. BILIRUBIN BLOOD TEST MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BILIRUBIN BLOOD TEST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIRECT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY INDIRECT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY TOTAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAZO, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ENZYMATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HPLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY SPECTROPHOTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY CIRRHOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BILIRUBIN BLOOD TEST MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES BILIRUBIN BLOOD TEST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 91. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 94. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 95. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 98. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 99. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 100. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 101. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 102. CANADA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 103. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 106. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 107. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 110. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 112. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 113. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 165. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 168. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 169. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 172. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 173. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 176. GERMANY BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 177. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 180. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 181. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 184. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 185. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 186. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 187. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 188. FRANCE BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 201. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 202. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 203. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 204. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 205. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 210. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 211. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 212. ITALY BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 213. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 216. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 217. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 220. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 221. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 222. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 223. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 224. SPAIN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 246. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 248. SAUDI ARABIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 258. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 260. SOUTH AFRICA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 261. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 264. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 265. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 268. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 269. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 270. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 271. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 272. DENMARK BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 281. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 282. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 283. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 284. NETHERLANDS BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 285. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 286. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 287. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 288. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 289. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 292. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 293. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 294. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 295. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 296. QATAR BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 297. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 300. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 301. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 304. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 305. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 306. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 307. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 308. FINLAND BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 317. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 318. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 319. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 320. SWEDEN BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 329. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 330. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 331. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2018-2024 (USD MILLION)
TABLE 332. NIGERIA BILIRUBIN BLOOD TEST MARKET SIZE, BY VIRAL HEPATITIS, 2025-2030 (USD MILLION)
TABLE 333. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 334. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 335. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
TABLE 336. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY METHOD, 2025-2030 (USD MILLION)
TABLE 337. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 340. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 341. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 342. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 343. EGYPT BILIRUBIN BLOOD TEST MARKET SIZE, BY V

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Bilirubin Blood Test market report include:
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Sysmex Corporation
  • bioMérieux SA
  • Ortho Clinical Diagnostics Inc
  • Mindray Medical International Limited
  • DiaSorin S.p.A

Table Information